患者来源抗体识别所有急性髓系白血病细胞表达的特异性CD43表位并在小鼠中具有抗白血病活性
研究从一名异基因造血干细胞移植后获得持久抗白血病反应患者的B细胞库中鉴定出供者来源抗体AT1413,该抗体特异性识别CD43上的新型唾液酸化表位(CD43s),后者在所有世界卫生组织2008分类的急性髓系白血病(AML)和骨髓增生异常综合征(MDS)中表达。AT1413在体外诱导抗体依赖性细胞介导的细胞毒性和补体依赖性细胞毒性,并在人源化小鼠模型中高效对抗AML细胞而不影响非恶性人髓系细胞,提示其作为治疗性抗体的潜力。
要点
- AT1413为供者来源抗体,特异性识别CD43s表位
- CD43s表达于所有WHO 2008分类的AML和MDS
- AT1413体外诱导ADCC和CDC,人源化小鼠中有效且不影响非恶性髓系细胞
核心结论
- AT1413识别所有WHO 2008类型AML和MDS表达的CD43s表位,并在体外和小鼠模型中显示抗白血病活性,提示其作为治疗性抗体的潜力。
研究设计与样本
- 利用异基因造血干细胞移植的肿瘤免疫治疗效应,搜索一名具有持久且强效移植物抗白血病反应患者的B细胞库以寻找AML特异性抗体。
主要发现
- 鉴定出供者来源抗体AT1413,特异性识别CD43上的新型唾液酸化表位(CD43s)。
- CD43s表达于所有世界卫生组织2008分类的AML和MDS。
- AT1413在体外诱导AML细胞的抗体依赖性细胞介导的细胞毒性和补体依赖性细胞毒性。
- 在人源化小鼠模型中,AT1413对AML细胞高效且不影响非恶性人髓系细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy has proven beneficial in many hematologic and nonhematologic malignancies, but immunotherapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) is hampered by the lack of tumor-specific targets. We took advantage of the tumor-immunotherapeutic effect of allogeneic hematopoietic stem cell transplantation and searched the B-cell repertoire of a patient with a lasting and potent graft-versus-AML response for the presence of AML-specific antibodies. We identified an antibody, AT1413, that was of donor origin and that specifically recognizes a novel sialylated epitope on CD43 (CD43s). Strikingly, CD43s is expressed on all World Health Organization 2008 types of AML and MDS. AT1413 induced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of AML cells in vitro. Of note, AT1413 was highly efficacious against AML cells in a humanized mouse model without affecting nonmalignant human myeloid cells, suggesting AT1413 has potential as a therapeutic antibody.
引用
- Gillissen MA, de Jong G, Kedde M, et al. Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. Blood Adv. 2017. PMID: 29296797. doi:10.1182/bloodadvances.2017008342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。